A Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Agilent Technologies Inc is not a strong buy for a beginner investor with a long-term strategy at this time. The stock is currently underperforming with bearish technical indicators, a recent earnings miss, and declining net income and EPS. While analysts maintain positive long-term ratings, the immediate sentiment and financial performance do not align with the user's investment goals. A hold is recommended until more favorable conditions arise.
The stock is exhibiting bearish momentum. The MACD is negative and expanding downward, RSI is at 26.41 (indicating oversold conditions but no clear reversal signal), and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 122.664, with key support at 117.122 and resistance at 128.207.
Analysts maintain long-term positive ratings, with multiple firms setting price targets above the current price (ranging from $150 to $180). Agilent is positioned as a leader in life sciences and diagnostics, with potential growth opportunities in liquid chromatography and mass spectrometry replacement cycles.
The company missed its Q1 2026 EPS consensus estimate, leading to a drop in stock price. Net income and EPS have declined YoY, and gross margin has also contracted. The options market sentiment is bearish, and technical indicators suggest further downside risk.
In Q1 2026, revenue increased by 6.96% YoY to $1.798 billion, but net income dropped by 4.09% YoY to $305 million. EPS decreased by 3.60% YoY to $1.07, and gross margin declined by 1.63% YoY to 52.61%. The financial performance reflects growth in revenue but declining profitability.
Analysts maintain a generally positive outlook on Agilent, with recent price targets ranging from $150 to $180. However, UBS recently lowered its price target to $165 from $180 following disappointing Q1 results. Despite short-term challenges, analysts view Agilent as well-positioned for long-term growth in life sciences and diagnostics.
